| Description |
Lomtegovimab (BI 767551) is a humanized anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19[1][2].
|
| Related Catalog |
|
| In Vitro |
Lomtegovimab 靶向 SARS-CoV-2 S 的 RBD，KD 值为 1.09 nM[2]。 Lomtegovimab 显示中和活性，对 SARS-CoV-2 S D614G, SARS-CoV-2 S B.1.1.7, SARS-CoV-2 BavPat1 (B.1) 的 IC50 值分别为 0.001、0.001、0.010 µg/mL[2]。
|
| In Vivo |
Lomtegovimab (40 mg/kg；i.p. 或 i.n.；一次；感染前三天) 保护 hACE2 转导的小鼠免受 SARS-CoV-2 感染[2]。 Animal Model: BALB/c mice (Ad_ACE2-mCherry)[2] Dosage: 40 mg/kg Administration: I.p. or I.n.; once; three days before infection Result: Led to a complete neutralization of infectious SARS-CoV-2 and slightly reduced amounts of viral RNA in the lungs of treated animals.
|
| References |
[1]. Halwe S, et al. Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. Viruses. 2021 Jul 29;13(8):1498.
|
